# AmerisourceBergen Corporation – Consensus ‘buy’ rating and 16.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/amerisourcebergen-corporation-consensus-buy-rating-and-16.2-upside-potential-6/4121131394
- Published: 2023-10-31T15:34:45+00:00
- Author: Charlotte Edwards

**AmerisourceBergen Corporation** which can be found using ticker (ABC) now have
14 confirmed analysts covering the stock with the consensus suggesting a rating 
of ‘buy’. The target price High/Low ranges between $225.00 and $190.00 with the 
average target price sitting at $209.57. Given that the stocks previous close was
at $180.39 and the analysts are correct then we can expect a percentage increase
in value of 16.2%. The 50 day moving average now sits at $181.99 and the 200 day
MA is $172.18. The market capitalization for the company is 36.15B. The stock price
for the company is currently $179.98 USD

 The potential market cap would be $41,997,301,323 based on the market consensus.

The company has a dividend yield of 1.09%. Other points of data to note are a P/
E ratio of 21.92, revenue per share of $1,247.29 and a 2.7% return on assets.

AmerisourceBergen Corporation is a global pharmaceutical sourcing and distribution
services company. The Company’s U.S. Healthcare Solutions segment distributes an
offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-
counter healthcare products, home healthcare supplies and equipment, and related
services to a wide variety of healthcare providers, including acute care hospitals
and health systems, independent and chain retail pharmacies, mail order pharmacies,
medical clinics, long-term care and alternate site pharmacies, and other customers.
The International Healthcare Solutions segment consists of businesses that focus
on international pharmaceutical wholesale and related service operations and global
commercialization services. This segment consists of Alliance Healthcare, World 
Courier, Innomar, Profarma, and Profarma Specialty. The Company also focuses on 
specialty services and a global platform of pharma manufacturer services capabilities.

Share on: